The Securities and Exchange Commission (SEC) has filed a rule with the Office of Information and Regulatory Affairs titled "Rescission of Policy Regarding Denials in Settlements of Enforcement Actions." If finalized, this would end the SEC's practice, in place since 1972, of allowing defendants to settle enforcement actions without admitting or denying allegations.
This change could significantly impact your disclosure controls, D&O insurance terms, and investor relations protocols, requiring immediate revisions.
What Changed
Since 1972, 17 CFR 202.5(e) has allowed parties to settle SEC enforcement matters without admission, as long as they don't deny the allegations. The policy aimed to prevent the impression that a decree or sanction was imposed without actual misconduct.
The U.S. Court of Appeals for the Ninth Circuit upheld this framework in 2025, affirming the SEC's authority to require non-denial as a settlement condition. Now, the Commission seems ready to reverse this policy.
Key Findings
Settlement dynamics shift. Without the neither-admit-nor-deny option, defendants must either admit the SEC's allegations or go to court. This removes the middle ground that has defined SEC enforcement for decades. Your legal team must recalibrate settlement value calculations, as the reputational and litigation costs of admission alter the equation.
Increased litigation risk. Admissions in SEC settlements can be used as evidence in shareholder derivative suits, securities class actions, and state enforcement proceedings. The Sarbanes-Oxley Act requires disclosure of material legal proceedings in Form 10-K and 10-Q filings. An admission of securities law violations creates a factual record that plaintiffs' attorneys can exploit. Adjust your litigation reserve methodology to account for this.
D&O insurance review. Directors and Officers liability policies often exclude coverage for admitted wrongdoing. If the SEC mandates admissions, you'll need to negotiate whether settlement discussions trigger coverage exclusions. Review your policy's "formal adjudication" and "deliberate fraudulent act" provisions now, before renewal negotiations.
Disclosure controls scrutiny. Under Item 9.01 of Form 8-K, you must disclose material definitive agreements within four business days. An SEC settlement with admissions qualifies as such an agreement. Your disclosure committee needs protocols for drafting 8-K language that satisfies Item 9.01 without adding litigation risk. Ensure accuracy without repeating every allegation verbatim.
Internal investigation standards tighten. When your Audit Committee initiates an internal investigation, the scope and findings may become evidence if the SEC requires admissions. This affects how you structure privilege, what you document, and whether you engage separate counsel for the company versus individual executives. AS 2201 requires your external auditor to evaluate management's assessment of internal control over financial reporting. If an SEC settlement admits control deficiencies, expect your auditor to revisit their Section 404 conclusions.
What This Means for Your Team
Your CFO and General Counsel need to reassess settlement authority thresholds. If every SEC settlement requires Board approval due to admissions triggering disclosure obligations, you can't delegate settlement authority to division-level executives.
Your investor relations team needs talking points for analysts who will question whether admitted violations indicate broader control weaknesses. The COSO Internal Control-Integrated Framework requires you to demonstrate that control deficiencies are remediated. An admission sets a public baseline against which analysts will measure your remediation progress.
Your enterprise risk management function should update the risk universe to reflect increased enforcement litigation costs. If fewer matters settle because defendants won't admit wrongdoing, adjust your legal spend forecast. PCAOB Auditing Standards require auditors to consider litigation as a potential indicator of material weakness in internal control over financial reporting.
Action Items by Priority
Immediate (next 30 days):
- Brief your Board's Audit Committee on the pending rule and its implications for settlement strategy.
- Review pending SEC inquiries and informal investigations to determine whether to accelerate settlement discussions before the rule takes effect.
- Audit your disclosure controls and procedures to ensure you can draft compliant 8-K disclosures for settlements with admissions.
Near-term (next 90 days):
- Engage D&O insurance brokers to assess whether current policy terms adequately cover defense costs if settlement discussions break down.
- Update your internal investigation protocols to address privilege considerations when findings may become part of an admitted settlement record.
- Train your disclosure committee on materiality thresholds for admitted control deficiencies versus remediated deficiencies.
Strategic (next 12 months):
- Revise your Code of Conduct and compliance training to emphasize that regulatory violations may result in public admissions, not confidential settlements.
- Update your COSO Internal Control-Integrated Framework assessment to identify control deficiencies that would be material if publicly admitted.
- Review your litigation reserve methodology with external auditors to ensure it reflects increased collateral litigation risk from admitted settlements.
